You may think you know how much Intel is struggling, but the reality is worse. The once-mighty American innovation powerhouse is losing market share in multiple areas that are critical to its ...

Gilead Sciences, GSK, ViiV Healthcare 1 to 3 years In June 2024, results from a trial of a new medicine to prevent HIV were announced—and they were jaw-dropping. Lenacapavir, a treatment ...

The most common brand of processor in laptops you can buy in the UK is Intel. However, Intel's myriad of marketing names for its various processors can make comparisons extremely tricky. In this guide ...

Intel plans to reach $15 billion in annual external foundry revenue by 2030. That ambitious target requires Intel 18A to deliver on its promises and launch on time. Any delays or missteps could be ...

J&J and ViiV – majority-owned by GlaxoSmithKline – hope that the streamlined process will help boost take-up of Cabenuva, which became the first long-acting alternative to daily ART last year.

ViiV is also working with Janssen to develop a once-monthly injectable HIV combo regimen, which recently reported positive phase 3 trial results. George Underwood 9 April, 2019 ...